About NCCN

NCCN Flash Update: NCCN Resources Updated for Soft Tissue Sarcoma

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), the NCCN Drugs & Biologics Compendium (NCCN Compendium®), the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), and the NCCN Radiation Therapy Compendium™ for Soft Tissue Sarcoma. These NCCN Guidelines® are currently available as Version 1.2018.

Footnote “13” modified with new references added: “Postoperative RT following surgery is discouraged for retroperitoneal/intra-abdominal sarcoma. If RT is not given prior to surgical resection, consider follow-up with possible preoperative EBRT at time of localized recurrence. In highly select cases where a postoperative EBRT boost is considered, intraoperative placement of clips at areas of high risk for recurrence or anticipated R1/R2 resection is encouraged. When external beam RT is used in these rare situations, sophisticated treatment planning with IMRT, IGRT, and/or protons can be used to improve the therapeutic ratio.”

Eribulin Footnote “h” is new to the page: Category 1 recommendation for liposarcoma.

Solitary fibrous tumor/hemangiopericytoma (SARC-F 2 of 6)

Sorafenib is a new agent with the following corresponding reference: Valentin T, Fournier C, Penel N, et al. Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs 2013;31(6):1626-1627.

About NCCN Flash Updates™
NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium, and other NCCN Content.